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Activation of the Unfolded Protein
Response in Vitiligo: The Missing Link?
Thierry Passeron1,2 and Jean-Paul Ortonne1
Vitiligo is characterized by a substantial loss of functional melanocytes in the
epidermis and sometimes in hair follicles. Genetic and pathophysiological studies
have provided strong evidence that vitiligo is a polygenetic, multifactorial disorder.
The key roles of oxidative stress within melanocytes and anti-melanocyte immune
responses have been addressed in many studies, but the relationship between
these mechanisms remains unclear. In this issue, Toosi et al. report the
upregulation of IL-6 and IL-8 after the activation of the unfolded protein response
(UPR) following exposure of melanocytes to phenols. Their results shed light on
the missing link between oxidative stress and immune responses in vitiligo.
Journal of Investigative Dermatology (2012) 132, 2502–2504; doi:10.1038/jid.2012.328
Oxidative stress in vitiligo
Vitiligo melanocytes long have been
known to have a low replication rate in
culture, requiring catalase supplementa-
tion for their growth and showing struc-
tural aberrations, such as dilated endo-
plasmic reticulum (Boissy et al., 1991).
High levels of hydrogen peroxide have
been found in the vitiligo epidermis
(Schallreuter et al., 1999). Indeed,
vitiligo melanocytes are the theater of
a redox balance loss because of high
levels of toxic catechol metabolites,
high free-radical levels, and defective
antioxidant machinery (Dell’anna and
Picardo, 2006). In culture, vitiligo mela-
nocytes are highly susceptible to
chemical and physical oxidative stress.
The overactivation of some sources of
reactive oxygen species (ROS), the role
of NADPH oxidase in ROS formation
caused by extracellular and intracellular
factors/conditions, and deficiencies in
one or more of the reducing agents and
detoxifying enzymes are responsible for
this redox homeostasis impairment. Dys-
function of catalase, superoxide dismu-
tase, glutathione peroxidase, thioredoxin
peroxidase, thioredoxin reductase, and
g-glutamyl transpeptidase has been repor-
ted extensively for vitiligo. The first
evidence supporting the concept that
stressed melanocytes could activate an
immune response was provided by the
identification of activated dendritic cells
after intrinsic damage to melanocytes due
to 4-tertiary butyl phenol exposure (Kroll
et al., 2005).
Vitiligo, an autoimune disorder
Studies of the infiltrate in perilesional
epidermis of vitiligo skin reveal predo-
minantly CD8þ cells (Lili et al., 2012).
A recent mouse model of vitiligo, with
a phenotype similar to that observed in
humans, was developed using melano-
cyte-specific CD8þ T cells (Harris et al.,
2012). Interestingly, in this model, the
inhibition of IFN-g with antibody pre-
vents the development of depigmen-
tation. Th1 and, more recently, the Th17
cytokine environment have been impli-
cated in the pathophysiology of vitiligo
(Wang et al., 2011; Kotobuki et al., 2012).
Dermal dendritic cells with activated
inflammasomes have been found at the
edges of vitiligo lesions, and they could
participate in the Th17 activation (Wang
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et al., 2011). Regulatory T cells (Tregs)
modulate Th1 and Th17 responses, and
there is growing evidence supporting their
key role in many immune disorders. Tregs
were recently shown to be reduced in
vitiligo skin (Klarquist et al., 2010). Some
data have also suggested impaired
function of Tregs that is associated with
a widespread activation of cytotoxic T
cells, in vitiligo (Lili et al., 2012). Interest-
ingly, in psoriasis, IL-6 allows cytotoxic
T cells to escape from Treg suppression
and promotes Th17 differentiation through
Stat3 phosphorylation (Goodman et al.,
2009). The upregulation of IL-6 produc-
tion by melanocytes under oxidative stress
through the activation of the UPR (Toosi
et al., 2012) could thus reduce Treg
modulation, leading to the activation of
the immune response against melanocytes
at a distance from initially affected sites.
Genetic background
Vitiligo is a polygenetic disorder charac-
terized by incomplete penetrance, mul-
tiple susceptibility loci, and genetic
heterogeneity associated with non-
genetic factors. Genetic association
studies with candidate genes and, more
recently, genome-wide linkage studies
of multiplex generalized vitiligo families
have revealed several susceptibility
genes. Some candidates are melano-
cytic genes (TYR, MC1R, OCA2-HERC2),
whereas others (HLA class I, II and III,
NLRP1, PTPN22, XBP1, SMOC2, FOXP1,
FOXP3, CCR6, CTLA4, LPP, TSLP, IL2RA,
UBASH3A, C1QTNF6, RERE, GZMB,
IFIH1, CD80, CLNK, BACH2, SLA,
CASP7, CD44, IKZF4, SH2B3, TOB2)
are involved in immune regulation and/
or are associated with other autoimmune
disorders (Spritz, 2012). Allelic variations
in these genes are not sufficient to deve-
lop vitiligo, as a concordance of only
23% was found in monozygotic twins
(Alkhateeb et al., 2003). Environmental
triggers thus appear mandatory at least
to initiate the immune process. In this
respect, we hypothesized that the activa-
tion of XBP1 in response to the oxidative
stress induced by phenols, as reported in
this issue by Toosi et al. (2012), could
be enhanced in subjects with specific
allelic variations in the XBP1 gene. Varia-
tions in other candidate genes involved in
immune regulation could act in the same
way in affected individuals to initiate an
immune ‘‘runaway’’. Interestingly, some
variants of TYR (S192Y and R402Q) have
recently been shown to modulate the
amount of TYR antigen presentation by
HLA-A*02:01 (Jin et al., 2012). These
variants are associated with an increased
risk of vitiligo, whereas HLA-A*02:01 is
also associated with a relatively good
response to melanoma immunotherapy.
Monobenzone exposition was also
shown to confer potent immunogenicity.
Ubiquitination of tyrosinase protein by
monobenzone exposure enhances the
presentation of this enzyme by HLA
class I and the secretion of melanocyte
antigens in response to monobenzone-
induced ROS (van den Boorn et al.,
2011). These data suggest that modu-
lation in the presentation of melanocyte
antigens could also affect the deregulated
immune responses against melanocytes in
patients.
Vitiligo pathogenesis
includes interplay
among oxidative
stress and immunity.
A complex network with many cellular
factors involved
Aside from the well-demonstrated role
of immune cells in vitiligo pathophysio-
logy, cytokines produced by keratino-
cytes and fibroblasts, such as stem cell
factor (SCF) and tumor necrosis factor-a
(TNF-a), also seem to have roles in
the disappearance of melanocytes (Lan
et al., 2009). Keratinocyte dysfunction,
with increased TNF-a and IL-6 produc-
tion, has been reported in vitiligo
patients (Moretti et al., 2009). Interest-
ingly, tacrolimus ointment, an effective
treatment for vitiligo, was shown to
decrease TNF-a and to increase IL-10
(a Th1 and Th17 suppressive cytokine)
within treated sites (Grimes et al., 2004;
Taher et al., 2009). SCF is secreted
by keratinocytes and fibroblasts. The
expression of SCF and its receptor,
cKIT, is decreased in lesional and peri-
lesional vitiligo skin (Kitamura et al.,
2004), and vitiligo-like depigmentation
has been reported in relation to tyrosine
kinase inhibitors such as imatinib,
which act on the cKIT pathway (Legros
et al., 2005). Last but not the least,
intrinsic defects in melanocytes prob-
ably have a crucial role in the patho-
physiology of vitiligo. Membrane lipid
defects in vitiligo melanocytes have
been reported, and they are respon-
sible for the generation of reactive
oxygen species (Dell’Anna et al.,
2010). It would be interesting to know
whether this type of intrinsic oxida-
tive stress also activates the UPR and
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Figure 1. Scheme of the interplay among factors involved in vitiligo pathophysiology. ER, endoplasmic
reticulum; SCF, stem cell factor; TGF-b1, transforming growth factor-b; TNF-a, tumor necrosis factor-a;
Treg, regulatory T cells; UPR, unfolded protein response; XBP1, X-box binding protein 1.
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upregulates IL-6 and IL-8, thus resuming
the pathway implicated with exposure
to phenols. We could hypothesize that
subtle defects in melanocyte catabolism,
in defense against oxidative stress, or in
melanocyte antigen presentation, affect-
ing only a subgroup of melanocytes
during embryogenesis, could, later in
life, trigger an immune response
against only those melanocytes. This
could explain the systematized lesions
observed in the segmental forms of
vitiligo. A scheme summarizing those
interplays is proposed in Figure 1.
Vitiligo is not limited to melanocytes,
even though their disappearance is
responsible for the clinical phenotype.
Upregulation of IL-6 and IL-8 following
activation of the UPR after oxidative
stress provides a clear link between oxi-
dative stress and the immune response.
A better understanding of these mecha-
nisms could provide new targets to
prevent or treat patients with vitiligo.
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